Monopar Therapeutics’ (MNPR) Hold Rating Reaffirmed at Jones Trading

Jones Trading reissued their hold rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a report published on Wednesday morning, Marketbeat Ratings reports.

A number of other analysts have also weighed in on MNPR. Piper Sandler reiterated an “overweight” rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Monopar Therapeutics Stock Down 13.3 %

NASDAQ:MNPR opened at $30.00 on Wednesday. The stock has a market capitalization of $183.39 million, a price-to-earnings ratio of -15.23 and a beta of 1.01. Monopar Therapeutics has a 52 week low of $1.72 and a 52 week high of $54.30. The firm has a 50 day moving average of $38.29 and a 200 day moving average of $24.88.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($1.87). As a group, analysts expect that Monopar Therapeutics will post -1.65 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares of the company’s stock, valued at approximately $28,778,925. The trade was a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 34.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $23,435,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics during the fourth quarter worth approximately $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics in the 4th quarter valued at $11,247,000. Point72 Asset Management L.P. purchased a new position in Monopar Therapeutics in the 4th quarter valued at $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Monopar Therapeutics during the 4th quarter worth $2,861,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.